Humacyte (NASDAQ:HUMA) 주식

HUMACYTE INC

Humacyte

Humacyte Inc is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Company's pipeline includes Vascular Trauma, PAD, Dailysis, Acellular Tissue Engineered Vessels, Advanced Organ Systems, Advanced Tissue Constructs.

Senator Tommy Tuberville

News

Politics

Personal Finance

ARKK

HUMA

INTC

PARA

PARAA

SOLV

SSBK

미국 의회 의원들의 주식 거래 활동은 위원회 임무를 포함한 이해 상충이 거래에 영향을 미칠 수 있다는 가능성으로 인해 투자자들로부터 지속적으로 관심을 끌고 있다. 잘 알려진 한 의회 의원은 금요일 시장 마감 무렵에 여러 거래를 공개했다.

미 상원 의원 토미 튜버빌은 여러 대형주의 매도와 매수 포지션 공개

Humacyte Inc

HUMAN PHEROMONE SCIENCE by Human Pheromone Sciences, Inc.

Human - United States Dollar

HUMAN HOLDINGS CO LTD by Human Holdings Co., Ltd.

Human Holdings Co Ltd

HUMAN UNITEC INTL INC by Human Unitec International, Inc.

Human Unitec International Inc

Humana Inc

Humanigen Inc

Humankind US Stock ETF

HUMANOID GLOBAL HLDGS CP by HUMANOID GLOBAL HLDGS CORP.

Humanoid Global Holdings Corp

Humanscape

Humatech Inc

RBC Capital analyst Ashish Sabadra reiterates APi Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/APG#NYSE">APG</a>) with a Outperform and maintains $52 price target.

Price Target

Reiteration

Analyst Ratings

RBC Capital Reiterates Outperform on APi Group, Maintains $52 Price Target

TRNR

Trading Halt: Halt status updated at 8:55:00 AM ET: Quotation Resumption: News and Resumption Times

GNLN

Apogee Enterprises Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APOG#NASDAQ">APOG</a>) shares traded higher Thursday after the company reported better-than-expected <a target="_blank" href="https://www.benzinga.com/pressreleases/25/06/b46135206/apogee-enterprises-reports-fiscal-2026-first-quarter-results" rel="noreferrer noopener">first-quarter fiscal 2025 results</a>.
Revenue rose 4.6% year over year to $346.62 million, topping the consensus estimate of $325.48 million. Growth was driven by $22 million in sales from the UW Solutions acquisition, partly offset by lower volume and a less favorable mix.
Adjusted earnings per share came in at 56 cents, beating the Street estimate of 47 cents.
Also Read: <a href="https://www.benzinga.com/markets/earnings/25/06/46128654/american-outdoor-stock-rallies-after-better-than-expected-q4-results" target="_blank" rel="noreferrer noopener">American Outdoor Stock Rallies After Better-Than-Expected Q4 Results</a>
Gross margin declined to 21.7% from 29.8%, impacted by $6.9 million in restructuring charges, higher aluminum costs, unfavorable product mix, and increased tariff expenses.
SG&amp;A expenses rose to 19.7% of sales, up 240 basis points, due to $8.4 million in restructuring charges and higher amortization from the UW Solutions deal.
Operating income fell to $6.9 million, impacted by $15.3 million in restructuring costs, unfavorable mix, higher aluminum and tariff expenses, and increased amortization.
Adjusted EBITDA declined to $34.4 million, with margin down to 9.9%, driven by mix shifts, higher aluminum and tariff costs, and lower incentive expense.
Net cash used in operations totaled $19.8 million, down from $5.5 million provided a year ago, due to lower earnings and a $13.7 million arbitration payment.
The company paid $5.5 million in dividends, and its long-term debt rose to $311 million, raising the leverage ratio to 1.6x. As of May 31, Apogee held $32.83 million in cash and cash equivalents.
Apogee began Phase 2 of Project Fortify in the first quarter to improve efficiency in its Architectural Services and Metals segments. The company expects $24 million to $26 million in pre-tax charges and annual savings of $13 million to $15 million. It recorded $15.3 million in costs this quarter and plans to complete the effort by the fourth quarter of fiscal 2026.
Ty R. Silberhorn, Apogee&#8217;s CEO, commented, &#8220;Although tariffs adversely impacted our first quarter results, we continue to execute our mitigation plans and barring any material change to tariff policies, we expect to be able to substantially mitigate the impact of tariffs on the second half of the fiscal year.&#8221;
Apogee raised its full-year 2025 net sales forecast to $1.40 billion to $1.44 billion, up from $1.37 billion to $1.43 billion versus the consensus of $1.388 billion.
Diluted EPS is now expected between $2.59 and $3.12, compared with the prior range of $2.54 to $3.19. Adjusted diluted EPS is projected at $3.80 to $4.20, up from $3.55 to $4.10 versus the consensus of $3.74.
The outlook includes a negative EPS impact of $0.35 to $0.45 from tariffs, mainly affecting the first half.
Apogee expects an effective tax rate of 33% and an adjusted rate of about 27.5%. Capital expenditures remain projected at $35 million to $40 million.
Price Action: APOG shares are trading higher by 13.4% to $45.00 premarket at last check Friday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/tech/25/06/46136541/elon-musk-backs-satya-nadellas-view-that-ai-must-produce-socially-useful-results-the-real-question-in-the-next-five-years-is" target="_blank" rel="noreferrer noopener">Elon Musk Backs Satya Nadella&#8217;s View That AI Must Produce&#8217; Socially Useful&#8217; Results: &#8216;The Real Question In The Next Five Years Is&#8230;&#8217;</a></li>
</ul>
Photo by  Pavel Kapysh via Shutterstock

Earnings

Guidance

Movers

APOG

Apogee's CEO Expects To Mitigate Tariffs Later This Year, Lifts Forecast

Inflation picked up again in May, snapping a two-month slowdown, raising fresh concerns that rising tariffs on foreign goods may start <a href="https://www.benzinga.com/news/econ-s">to strain U.S. consumers.</a>
The Personal Consumption Expenditures (PCE) price index rose 2.3% in May from a year earlier, matching economists&#8217; expectations and marking a slight uptick from April's upwardly revised 2.2%. 
On a monthly basis, the PCE increased 0.1%, in line with consensus and unchanged from April.
Yet, the core PCE index, which strips out volatile food and energy prices and is closely monitored by Fed policymakers as the most reliable inflation metric, accelerated to 2.7% year-over-year from the upwardly revised 2.6% in April, exceeding the economic estimate of 2.6%.
Month-over-month, core PCE climbed 0.2%, doubling April's 0.1% pace and exceeding forecasts. 
The uptick in inflation, particularly in the Fed&#8217;s favorite gauge, comes amid concern over the Trump administration's new tariff regime, which targets a wide range of imported goods. 
<h3 class="wp-block-heading">Households Cut Back Spending As Incomes Drop</h3>
Despite rising inflation pressures, American consumers reduced their spending in May, while personal income experienced a sharp decline.
The Bureau of Economic Analysis reported that personal income fell by 0.4% month-over-month, missing expectations of a 0.3% rise. In April, income had surged 0.7%.
Notably, this marked the first contraction in personal income since September 2021. 
Meanwhile, personal spending also contracted by 0.1%, a $29.3 billion decrease, against expectations for a modest 0.1% increase. The pullback in consumption follows a revised 0.2% gain in April.
The biggest hit came in goods, especially vehicles. 
Spending on motor vehicles and parts tumbled $49.3 billion, followed by gasoline and other energy goods, which declined $19.8 billion. Spending on food services and accommodations slipped by $10.6 billion.
<h3 class="wp-block-heading">Market Reactions</h3>
Despite the rise in inflation, the U.S. dollar weakened following the data release, pressured by sharper-than-expected declines in income and consumer spending.
Futures on major U.S. equity indexes climbed between 0.3% and 0.4% in Friday's premarket, with both the S&amp;P 500 and Nasdaq 100 poised to extend their record-setting rallies.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/economic-data/25/06/46124290/sp-500-hits-record-highs-and-history-says-the-best-is-yet-to-come">S&amp;P 500 Trades At Record Highs—And History Says The Best Is Yet To Come (UPDATED) </a></li>
</ul>
Photo: Shutterstock

Macro Economic Events

Econ #s

Economics

Federal Reserve

Inflation Is Heating Up Again—Are Tariffs To Blame?

WIIM

OKLO

Shares of nuclear stocks are trading higher following a Reuters report suggesting President Trump is planning executive orders to boost energy supply for AI.

Cantor Fitzgerald analyst Brett Knoblauch maintains HIVE Digital Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HIVE#NASDAQ">HIVE</a>) with a Overweight and raises the price target from $5 to $5.5.

HIVE

Cantor Fitzgerald Maintains Overweight on HIVE Digital Technologies, Raises Price Target to $5.5

<a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4457514-1&amp;h=3748747261&amp;u=https%3A%2F%2Fwww.neurocrine.com%2F&amp;a=Neurocrine+Biosciences%2C+Inc.">Neurocrine Biosciences, Inc.</a>&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NBIX#NASDAQ">NBIX</a>) today announced new patient-reported post-hoc data from the KINECT&#xAE;-HD study highlighting significant reductions in both cognitive and motor-related burdens among adults treated for Huntington's disease chorea with once-daily <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4457514-1&amp;h=1598651954&amp;u=https%3A%2F%2Fwww.ingrezza.com%2Fhuntingtons-chorea&amp;a=INGREZZA%C2%AE+(valbenazine)+capsules">INGREZZA&#xAE; (valbenazine) capsules</a>. KINECT-HD is the first and only clinical study to demonstrate measurable changes in cognitive and motor disease burden with a vesicular monoamine transporter 2 inhibitor (INGREZZA) in patients treated for chorea. These analyses will be presented at the 2025 Advanced Therapeutics in Movement &amp; Related Disorders Congress hosted by the Parkinson &amp; Movement Disorder Alliance in Washington, D.C.

NBIX

Neurocrine Reports Post-Hoc Data Demonstrating Cognitive, Motor Disease Burden With INGREZZA In HD Chorea

William Blair analyst Ryan Merkel initiates coverage on James Hardie Industries (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JHX#NYSE">JHX</a>) with a Outperform rating.

Initiation

William Blair Initiates Coverage On James Hardie Industries with Outperform Rating

Cantor Fitzgerald analyst Timur Ivannikov reiterates ProQR Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRQR#NASDAQ">PRQR</a>) with a Overweight and maintains $8 price target.

PRQR

Cantor Fitzgerald Reiterates Overweight on ProQR Therapeutics, Maintains $8 Price Target

Major U.S. corporations are increasingly adding Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) to their balance sheets, raising concerns about potential market risks as the trend accelerates under <a href="https://www.benzinga.com/crypto/cryptocurrency/25/06/46131815/trumps-crypto-advisor-david-sacks-says-july-will-be-a-big-month-says-president-supports-legislation-on-market-structure-and-stablecoins">President Donald Trump's administration</a>.
Companies like Trump Media &amp; Technology Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DJT#NASDAQ">DJT</a>) are driving this surge, recently announcing plans to invest around $2.5 billion in Bitcoin through stock and debt sales.
Trump's pro-crypto stance has significantly reshaped the regulatory landscape, Politico <a href="https://www.politico.com/news/2025/06/27/trump-bitcoin-treasury-wall-street-warren-00423673">reported</a>.
His administration's rollback of enforcement actions and push for crypto-friendly legislation have emboldened corporate America to embrace digital assets more aggressively. 
According to Standard Chartered, more than 60 publicly traded companies globally now hold over 673,000 Bitcoin, valued at approximately $75 billion as of May's end. 
Trump Media, among the most notable participants, is allocating substantial capital to Bitcoin, with CEO Devin Nunes calling it "an apex instrument of financial freedom."
Also Read: <a href="https://www.benzinga.com/crypto/cryptocurrency/25/06/46121954/retail-investors-can-now-trade-spacex-shares-heres-how">Retail Investors Can Now Trade SpaceX Shares: Here&#8217;s How</a>
Trump family members, including Eric Trump, have publicly championed Bitcoin adoption at recent industry events, reflecting a broader shift in sentiment where companies view Bitcoin as a viable treasury asset alongside traditional holdings like U.S. Treasuries.
Despite the enthusiasm, several lawmakers and experts are voicing caution. 
Senator Elizabeth Warren (D-Mass.) has warned that widespread corporate exposure to Bitcoin could amplify the economic fallout in the event of a future crypto crash, potentially leading to business failures and job losses across sectors.
Nic Carter, a partner at Castle Island Ventures, likened the current buildup of corporate Bitcoin holdings to &#8220;kindling&#8221; that could fuel a market collapse. 
Columbia University's Omid Malekan echoed the sentiment, pointing out the crypto industry's repeated cycles of overconfidence followed by painful corrections.
The practice, popularized by Michael Saylor's Strategy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>), has since been adopted by other firms like Japan's Metaplanet (OTC:<a class="ticker" href="https://www.benzinga.com/stock/MTPLF#OTC">MTPLF</a>) and the Trump-backed American Bitcoin.
These companies raise capital at low cost through stock and debt markets and use the proceeds to buy Bitcoin, a strategy that has driven their stock prices higher.
However, critics like investor Jim Chanos argue that these gains are unsustainable. 
He believes the valuations of such firms could plummet if Bitcoin prices fall, warning that many of these companies are not adding meaningful value beyond buying Bitcoin itself.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/crypto/cryptocurrency/25/06/46119440/why-did-this-uae-based-fund-just-purchase-100m-worth-of-trump-affiliated-wlfi-tokens">Why Did This UAE-Based Fund Just Purchase $100M Worth Of Trump-Affiliated WLFI Tokens?</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Short Sellers

$BTC

MSTR

MTPLF

Corporate Bitcoin Buying Spree: Booming Strategy Or Ticking Financial Time Bomb?

BURU

NUBURU shares are trading higher after the company said the regulatory approval process for its acquisition of Tekne SpA is progressing 'positively and in line with expectations.'

LAES

WKEY

WISeKey's Subsidiary WISeSat.Space Is On Target To Deploy 100-Satellite Constellation By 2027 In Cooperation With WISekey And SEALSQ

Government

Regulations

NUBURU Says Regulatory Approval Process For Acquisition Of Tekne SpA Is 'progressing positively and in line with expectations'

Cantor Fitzgerald analyst Eric Schmidt reiterates Avidity Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNA#NASDAQ">RNA</a>) with a Overweight and maintains $96 price target.

Cantor Fitzgerald Reiterates Overweight on Avidity Biosciences, Maintains $96 Price Target

Stock Split

HSDT

Helius Medical Technologies Announces 1-For-50 Reverse Split Of Its Class A Common Stock

Offerings

OTRK

Ontrak Health Prices Public Offering Of 6,666,667 Shares And 26,666,668 Warrants At Combined Public Offering Price Of $0.60 Per Share And Accompanying Warrant; Gross Proceeds ~$4M

Omeros Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMER#NASDAQ">OMER</a>) today announced the recent submission of a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for narsoplimab for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA).
The MAA includes response-based analyses in narsoplimab-treated TA-TMA patients as well as analyses comparing overall survival between narsoplimab-treated patients and a well-matched external control group. Collectively, the results demonstrate a 61% response rate and, compared to the matched external control, a three-fold improvement in overall survival. The submission also includes outcomes in over 130 TA-TMA patients treated with narsoplimab under Omeros' expanded access program.
Narsoplimab has been granted orphan drug designation by the EMA for treatment in hematopoietic stem cell transplant, enabling review of the MAA through the centralized procedure. This allows for a single marketing authorization to cover all EU member states and the European Economic Area countries of Iceland, Liechtenstein and Norway.
The review procedure begins in mid-July and will follow a standard review timeline. The Committee for Medicinal Products for Human Use (CHMP) will conduct the scientific assessment and will issue an opinion at the end of the review. This opinion is typically adopted by the European Commission, with a final decision expected in mid-2026.
The MAA submission follows the acceptance for review by the U.S. Food and Drug Administration (FDA) of the resubmission of the Biologics License Application (BLA) for narsoplimab for the treatment of TA-TMA. The resubmission was assigned a Prescription Drug User Fee Act (PDUFA) target action date of September 25, 2025.

OMER

Omeros Submits MAA To EMA For Narsoplimab For Treatment Of Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy

JMP Securities analyst Jonathan Wolleben reiterates ProQR Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRQR#NASDAQ">PRQR</a>) with a Market Outperform and maintains $8 price target.

JMP Securities Reiterates Market Outperform on ProQR Therapeutics, Maintains $8 Price Target

CISO

CISO Global Files Renewal Of S-3 Shelf Registration, Reducing Total Shelf From $300M To $100M

Press Releases

General

Humacyte Announces Publication of the Budget Impact Model (BIM) for Symvess™ (acellular tissue engineered vessel-tyod) in the Journal of Medical Economics

Financing

Humacyte, Inc. Announces Proposed Public Offering of Common Stock

Humacyte, Inc. Announces Pricing of Public Offering of Common Stock

Humacyte to Present Fourth Quarter and Full Year Financial Results and Provide Corporate Update on March 28, 2025

Humacyte Announces Fourth Quarter and Year End 2024 Financial Results and Provides Business Update

Humacyte to Present First Quarter Financial Results and Provide Corporate Update on May 13, 2025

Humacyte Announces First Quarter 2025 Financial Results and Provides Business Update

Humacyte to Present at the H.C. Wainwright 3rd Annual BioConnect Investor Conference at Nasdaq

Humacyte Clinical Results in High-Risk Dialysis Patients from V007 Pivotal Phase 3

Health Care

Results from Humacyte's V007 Pivotal Phase 3 AV Access Study Highlighted by Presentation at the Society for Vascular Surgery Meeting

Comments

Humacyte

뉴스

파트너 / 기고자

벤징가 글로벌